The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

This is a summary of: Liu. H. et al. Viral RNA blocks circularization to evade host codon usage control. Nature ...

In a recent study posted to the bioRxiv* preprint server, researchers described a messenger ribonucleic acid (mRNA)-lipid nanoparticle mpox vaccine encoding four conserved mpox virus surface proteins ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

Please provide your email address to receive an email when new articles are posted on . There are now three FDA approved RSV vaccines. This marks the first mRNA vaccine approved by the FDA for the ...

Moderna, Inc. MRNA announced that it has started dosing healthy participants in a phase I study, which is evaluating the safety, tolerability and immunogenicity of its mRNA-based vaccine candidate, ...

In a recent study posted to the bioRxiv* preprint server, researchers in China demonstrated the efficacy of three messenger ribonucleic acid (mRNA) technology-based Monkeypox virus (MPXV) vaccines in ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Kostaive (zapomeran) mRNA COVID-19 ...

Bayer is suing Pfizer, Moderna, BioNTech and Johnson & Johnson, alleging Covid-19 vaccines infringed patented mRNA technology ...

Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 ...